NPS Pharmaceuticals, which develops treatment for rare diseases, is looking for a buyer, the Wall Street Journal reported. The company's shares rose as much as 12 percent to $39.88, their highest in 13 years.NPS Pharma's advisers at Goldman Sachs Group Inc have started contacting other companies to gauge their interest, WSJ said, citing people familiar with the matter. (on.wsj.com/1xvwHY2)Bloomberg reported last month that London-based drugmaker Shire Plc was considering an offer for NPS and the timing of the possible bid would depend on whether the U.S. health regulator approves NPS's hormone replacement therapy Natpara.NPS Pharmaceuticals was not immediately available for comment.
The Goldman Sachs Group, Inc. (Goldman Sachs), is a global investment banking, securities and investment management firm that provides a range of financial services to a substantial and diversified client base that includes corporations, financial institutions, governments and high-net-worth individuals. Shares of GS fell by 3.25% or $-6.31/share to $188.10. In the past year, the shares have traded as low as $151.65 and as high as $198.06. On average, 2986180 shares of GS exchange hands on a given day and today's volume is recorded at 2632360.
NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. Shares of NPSP traded higher by 6.43% or $2.3/share to $38.05. In the past year, the shares have traded as low as $22.11 and as high as $39.68. On average, 1544910 shares of NPSP exchange hands on a given day and today's volume is recorded at 3422763.
Shire plc (Shire) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shares of SHPG fell by 1.4% or $-2.93/share to $206.08. In the past year, the shares have traded as low as $140.06 and as high as $264.98. On average, 1906580 shares of SHPG exchange hands on a given day and today's volume is recorded at 799505.
Source
